Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY19.25
-0.43 (-2.19%)
CN SHH Healthcare Biotechnology
Address
410 Longxi Avenue 51000
Guangzhou, CN
Guangzhou, CN
CEO
Guoqiang Ke
Website
dslyy.com
IPO
2017-07-31
ISIN CNE100002RG2
Description
Established in 1999, DaShenLin Pharmaceutical Group Co., Ltd. is a Chinese company based in Guangzhou. It operates across the pharmaceutical supply chain, engaging in the production, distribution, and direct sale of medicinal products throughout the country.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY19.25
-0.43 (-2.19%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.54
Float Shares
376.05M
Free Float %
33.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.32% | +1.19% | +8.41% | -2.71% | -0.80% | +6.13% | +2.69% | -32.90% | -54.80% | +41.56% | +41.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
19.25
DCF (Unlevered)
119.81
+522.4%
DCF (Levered)
226.08
+1,074.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.19
Grey zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+3.8% ★ Q1'26: +0.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+33.3% ★ Q1'26: +12.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+15.8% ★ Q1'26: +12.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+7.0% ★ Q1'26: +10.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+9.7% ★ Q1'26: +48.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.3% ★ Q1'26: -1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.70× Q1'26: 0.88× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 9 EPS Ana. |
Dec 2027 10 Rev. Ana. 10 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.42B
est: 7.54B (-1.6%)
|
8.86B
est: 8.95B (-1.0%)
|
11.14B
est: 10.88B (+2.4%)
|
14.58B
est: 14.56B (+0.1%)
|
16.76B
est: 17.35B (-3.4%)
|
21.25B
est: 20.57B (+3.3%)
|
24.53B
est: 25.88B (-5.2%)
|
26.50B
est: 26.55B (-0.2%)
|
27.50B
est: 27.39B (+0.4%)
|
29.76B
29.05B – 30.37B
+8.7% YoY
|
32.90B
30.82B – 34.42B
+10.5% YoY
|
36.22B
35.75B – 36.69B
+10.1% YoY
|
| EBITDA |
727.81M
est: 781.91M (-6.9%)
|
831.28M
est: 928.42M (-10.5%)
|
1.06B
est: 1.13B (-6.2%)
|
1.53B
est: 1.51B (+1.5%)
|
1.31B
est: 1.80B (-27.4%)
|
1.81B
est: 2.13B (-15.2%)
|
3.24B
est: 4.85B (-33.1%)
|
3.13B
est: 4.97B (-37.0%)
|
3.47B
est: 5.13B (-32.3%)
|
5.57B
5.44B – 5.69B
+8.7% YoY
|
6.16B
5.77B – 6.45B
+10.5% YoY
|
6.78B
6.70B – 6.87B
+10.1% YoY
|
| EBIT |
650.00M
est: 551.28M (+17.9%)
|
714.21M
est: 654.57M (+9.1%)
|
916.26M
est: 795.94M (+15.1%)
|
1.36B
est: 1.06B (+28.0%)
|
1.10B
est: 1.27B (-13.2%)
|
1.59B
est: 1.50B (+5.7%)
|
1.80B
est: 1.77B (+1.4%)
|
1.55B
est: 1.82B (-14.9%)
|
1.93B
est: 1.87B (+2.8%)
|
2.04B
1.99B – 2.08B
+8.7% YoY
|
2.25B
2.11B – 2.36B
+10.5% YoY
|
2.48B
2.45B – 2.51B
+10.1% YoY
|
| Net Income |
474.96M
est: 535.20M (-11.3%)
|
531.63M
est: 579.81M (-8.3%)
|
702.66M
est: 773.36M (-9.1%)
|
1.06B
est: 1.05B (+1.3%)
|
791.23M
est: 1.09B (-27.7%)
|
1.04B
est: 1.11B (-6.3%)
|
1.17B
est: 906.67M (+28.7%)
|
914.75M
est: 1.06B (-13.3%)
|
1.24B
est: 1.20B (+3.4%)
|
1.48B
1.37B – 1.56B
+24.0% YoY
|
1.71B
1.57B – 1.85B
+15.3% YoY
|
1.94B
1.52B – 2.12B
+13.5% YoY
|
| SGA |
2.27B
est: 2.18B (+3.9%)
|
2.90B
est: 2.59B (+11.9%)
|
3.42B
est: 3.15B (+8.4%)
|
4.17B
est: 4.22B (-1.1%)
|
5.19B
est: 5.02B (+3.2%)
|
6.27B
est: 5.96B (+5.2%)
|
6.81B
est: 6.27B (+8.6%)
|
7.42B
est: 6.43B (+15.5%)
|
1.34B
est: 6.63B (-79.9%)
|
7.21B
7.04B – 7.35B
+8.7% YoY
|
7.97B
7.46B – 8.34B
+10.5% YoY
|
8.77B
8.66B – 8.88B
+10.1% YoY
|
| EPS |
0.47
est: 0.47 (-0.8%)
|
0.49
est: 0.51 (-4.0%)
|
0.63
est: 0.68 (-8.0%)
|
0.94
est: 0.93 (+1.2%)
|
0.70
est: 0.97 (-27.7%)
|
0.91
est: 0.96 (-5.6%)
|
1.03
est: 0.80 (+28.7%)
|
0.81
est: 0.91 (-11.2%)
|
1.08
est: 1.05 (+2.7%)
|
1.30
1.20 – 1.36
+23.1% YoY
|
1.50
1.37 – 1.62
+15.7% YoY
|
1.70
1.33 – 1.85
+13.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
4.24B
OE per share TTM
3.73
Owner's Yield
19.91%
Maintenance CapEx ratio
21.82%
Maint CapEx / Avg PPE
25.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 30 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.94% | 665.7K | 0.95% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.07% | 24.8K | 0.65% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 59.7K | 0.44% |
| 4 | Dimensional - Emerging Markets High Profitability ETF DEHP | 0.01% | 41.1K | 0.44% |
| 5 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 84.3K | 0.19% |
| 6 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 10.9K | 0.58% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 281.9K | 0.39% |
| 8 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.00% | 1.6K | 0.15% |
| 9 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 110.8K | 0.17% |
| 10 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 110.8K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
44.3K
Shares Outstanding
1.14B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changcheng Chen | Deputy General Manager | — | male |
| Guangzhi Peng | Financial Director & Secretary to the Board | — | male |
| Guoqiang Ke | GM & Director | — | male |
| Hong Chen | Deputy General Manager | — | male |
| Qun Fei Tan | Deputy GM & Director | — | female |
| Tuo Ji Ke | Deputy General Manager | — | male |
| Xin Jiang | Deputy General Manager | — | female |
| Zhi Hui Chen | Chairman of Supervisory Board & Deputy Director of Human Resources Department - Guangdong Province | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603233.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
